文献速递产科母胎医学

妊娠早期低剂量阿司匹林相关的母体、胎儿及新生儿严重不良事件:ASPIRIN 试验的二次分析

Maternal, fetal, and neonatal serious adverse events associated with low-dose aspirin during the first trimester of pregnancy: A secondary analysis of the Aspirin Supplmentation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) trial.
PubMed 文献 · Am J Obstet Gynecol MFM · 2025-08-18

ASPIRIN 试验二次分析纳入 11,879 例单胎初产妇,随机接受低剂量阿司匹林(LDA,81 mg/d)或安慰剂,按妊娠 11 0/7 周前与之后开始暴露分层。结果显示 LDA 启动时机与母体、胎儿及新生儿严重不良事件无显著差异(所有交互作用 P>.05),先天畸形在胚胎期与胎儿期暴露间也无显著差异(交互作用 P 值=.095)。

要点

  • LDA 在妊娠 11 0/7 周前启动与之后启动相比,母体、胎儿及新生儿严重不良事件无显著差异(所有交互作用 P>.05)。
  • 先天畸形在胚胎期(<9 0/7 周)与胎儿期暴露间无显著差异(交互作用 P 值=.095)。
  • 在暴露依从性≥90% 的参与者中结果保持一致。

核心结论

  • 妊娠 11 0/7 周前启动 LDA(81 mg/d)可能不增加母体、胎儿或新生儿严重不良事件或先天畸形的风险,为妊娠早期 LDA 暴露的安全性提供了令人安心的证据。

研究设计与样本

  • ASPIRIN 试验的二次分析,纳入 11,879 例单胎初产妇,随机接受 LDA(81 mg/d)或安慰剂,暴露启动时间在妊娠 6 0/7-13 6/7 周之间。
  • 按 LDA 启动时的孕龄(<11 0/7 周 vs ≥11 0/7 周)分析严重不良事件。
  • 先天畸形按胚胎期(<9 0/7 周)或胎儿期启动治疗进行评估。
  • 在 ASPIRIN 试验安全性人群(至少接受一剂 LDA 或安慰剂)及暴露依从性≥90% 的亚组中,通过逻辑回归模型进行交互作用检验。

主要发现

  • 在 11,879 例合格参与者中,62%(n=7324)在 11 0/7 周前启动分配暴露,38%(n=4555)在较晚孕龄启动 LDA 或安慰剂。
  • 在该人群中,84.4%(n=10,030)对干预的依从性≥90%。
  • LDA 或安慰剂依从性≥90% 的比例在各层间相似(<11 0/7 周组 84.6% [n=6195] vs ≥11 0/7 周组 84.2% [n=3835],P=.570)。
  • 基于 LDA 启动时机,上述母体、胎儿或新生儿不良事件无显著差异(所有交互作用 P>.05)。
  • 先天畸形在胚胎期与胎儿期暴露间无显著差异(交互作用 P 值=.095)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low-dose aspirin (LDA) has been shown to reduce the risk of preterm preeclampsia, particularly when initiated early in pregnancy. However, the safety of starting LDA before 11 0/7 weeks of gestation remains unclear. OBJECTIVE: To assess whether initiating LDA before 11 0/7 weeks of gestation is associated with increased maternal, fetal, or neonatal serious adverse events compared to later initiation. STUDY DESIGN: This secondary analysis of the ASPIRIN (Aspirin Supplmentation for Pregnancy Indicated Risk Reduction In Nulliparas) trial included 11,879 nulliparous women with singleton pregnancies randomized to receive LDA (81 mg/d) or placebo between 6 0/7-13 6/7 weeks of gestation. Severe adverse events (ie, maternal death, antepartum hemorrhage, postpartum hemorrhage, anemia, preeclampsia or eclampsia, preterm labor, hypertension admission, fever or infection, fetal loss, neonatal death up to 28 days, miscarriage, abortion, or medical termination of pregnancy, and congenital anomalies) were analyzed based on gestational age at LDA initiation (<11 0/7 vs ≥11 0/7 weeks). Furthermore, congenital anomalies were assessed for therapy initiated during the embryonic (ie, <9 0/7 weeks) or fetal period. Interaction tests were performed via logistic regression models on the ASPIRIN trial safety population (ie, participants who received at least one dose of LDA or placebo) and on the subset of participants who had an adherence to the exposure of ≥90%. RESULTS: Among the 11,879 eligible participants for this secondary analysis, 62% (n=7324) initiated the allocated exposure before 11 0/7 weeks vs 38% (n=4555) that initiated LDA or placebo at a later gestational age. Furthermore, in this population, 84.4% (n=10,030) had an adherence to the intervention of 90% or more. Moreover, the proportion of adherence of ≥90% to LDA or placebo was similar between strata (84.6% [n=6195] for <11 0/7 vs 84.2% [n=3835] ≥11 0/7 weeks, P=.570). No significant differences were observed in the maternal, fetal, or neonatal adverse events described above based on the timing of LDA initiation (P>.05 for all interactions). Likewise, congenital anomalies did not significantly differ between embryonic and fetal exposure periods (interaction P-value = .095). Results remained consistent in participants who had an adherence to the exposure of ≥90%. CONCLUSIONS: LDA (81 mg/d) initiated before 11 0/7 weeks of gestation may not increase the risk of maternal, fetal, or neonatal serious adverse events or congenital anomalies. These findings provide reassuring evidence of the safety of LDA exposure during early pregnancy. El resumen está disponible en Español al final del artículo.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Rodriguez-Sibaja MJ, Galvez-Rubalcava N, Hagerman-Sucar G, et al. Maternal, fetal, and neonatal serious adverse events associated with low-dose aspirin during the first trimester of pregnancy: A secondary analysis of the Aspirin Supplmentation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) trial. Am J Obstet Gynecol MFM. 2025. PMID: 40835027. doi:10.1016/j.ajogmf.2025.101768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。